Hepion pharmaceuticals, inc. (CTRV)
Income statement / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13
Costs and expenses:
Research and development

1,063

846

755

518

1,042

2,167

2,122

2,260

3,200

3,963

3,259

2,944

4,317

3,129

4,024

3,186

4,042

3,765

3,589

2,606

1,823

384

218

72

9

13

122

General and administrative

1,178

1,064

939

1,403

1,953

1,684

1,761

1,600

1,483

1,874

1,956

1,963

1,704

1,747

1,769

1,465

1,471

1,078

1,785

1,791

1,280

698

650

386

154

166

17

Total operating expenses

-

-

1,695

1,921

-

-

3,884

3,861

-

-

-

4,908

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-2,242

-1,910

-1,695

-1,921

-2,995

-3,852

-3,884

-3,861

-4,683

-5,838

-5,216

-4,908

-6,022

-4,877

-5,794

-4,652

-5,514

-4,844

-5,375

-4,397

-3,104

-1,082

-869

-458

-163

-180

-140

Other income (expense):
Change in fair value of debt

-3

-22

-94

-59

-

-14

31

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

15

441

98

-

55

231

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative instruments-warrants and contingent consideration

84

128

249

95

601

3,765

55

635

998

64

7,266

-2,710

-391

60

-

-735

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

6

4

1

0

Total other income (expense)

-

-

-

-62

-

-

-

635

-

-

-

-2,710

-

-

-

-

-

-

-

-

-

-

5,250

-8,852

-4

-1

-0

Change in fair value of derivative instruments-warrants

-

-

-

-

-

-

-

-

-

-

-

-

391

-

-

-

-2,483

-

0

0

0

387

-

8,846

-

-

-

Loss before income taxes

-2,160

-1,819

-1,981

-1,983

-2,572

-157

-4,029

-3,226

-3,684

-5,774

2,049

-7,618

-6,413

-

-

-3,917

-3,030

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

-

-961

-

0

0

0

-536

-

-

-

-

-1,908

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-1,894

-1,819

-1,020

-1,983

-2,572

-157

-4,029

-2,690

-1,736

-5,774

2,049

-7,618

-4,505

-4,816

-

-3,917

-3,030

-4,844

-

-

-3,104

-1,470

-

-9,311

-168

-

-

Deemed dividend (see note 6)

-1

8

5,412

24

-

8,805

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,816

-

-

-

-4,844

-

-4,397

-

-

-

-

-

-

-

Series A and B convertible preferred stock beneficial conversion feature accreted as a dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,000

4,844

-

-

-

-

-

-

Comprehensive Loss Attributable to Common Shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,397

-

-

-

-

-

-

-

Net loss attributable to common shareholders

-1,892

-1,828

-6,432

-2,008

-2,218

-8,962

-4,029

-2,690

-1,736

-5,774

-

-

-

-

-

-

-

-

-

-

-7,949

-

4,381

-9,311

-168

-182

-140

Weighted Average Common Shares Outstanding:
Basic

-

-

-

17,508

-

-

-

10,124

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

17,508

-

-

-

10,124

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted

-

3,453

859

-

-

202

152

-

-

7,506

7,506

63,301

60,053

37,919

-

27,297

26,642

22,289

22,260

22,273

22,273

20,211

18,536

14,735

9,000

9,000

9,000

Net loss per Common Share: (see note 12)
Basic

-

-

-

-0.11

-

-

-

-0.27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-0.11

-

-

-

-0.27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted

-

-0.53

-7.48

-

-

-44.27

-26.45

-

-

-0.77

0.27

-0.12

-0.08

-0.13

-

-0.14

-0.11

-0.22

-0.26

-0.33

-0.36

-0.07

0.26

-0.63

-0.02

-0.02

-0.02